Effect of mushroom Agaricus blazei on immune response and development of experimental cerebral malaria

Cynthia H. Val, Fátima Brant, Aline S. Miranda, Flávia G. Rodrigues, Bruno C L Oliveira, Elândia A. Santos, Diego R R Assis, Lísia Esper, Bruno C. Silva, Milene A. Rachid, Herbert B. Tanowitz, Antônio L. Teixeira, Mauro M. Teixeira, Wiliam C B Régis, Fabiana S. Machado

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Cerebral malaria (CM) is debilitating and sometimes fatal. Disease severity has been associated with poor treatment access, therapeutic complexity and drug resistance and, thus, alternative therapies are increasingly necessary. In this study, the effect of the administration of Agaricus blazei, a mushroom of Brazilian origin in a model of CM caused by Plasmodium berghei, strain ANKA, was investigated in mice. Methods: C57BL/6 mice were pre-treated with aqueous extract or fractions of A. blazei, or chloroquine, infected with P. berghei ANKA and then followed by daily administration of A. blazei or chloroquine. Parasitaemia, body weight, survival and clinical signs of the disease were evaluated periodically. The concentration of pro-and anti-inflammatory cytokines, histopathology and in vitro analyses were performed. Results: Mice treated with A. blazei aqueous extract or fraction C, that shows antioxidant activity, displayed lower parasitaemia, increased survival, reduced weight loss and protection against the development of CM. The administration of A. blazei resulted in reduced levels of TNF, IL-1β and IL-6 production when compared to untreated P. berghei-infected mice. Agaricus blazei (aqueous extract or fraction C) treated infected mice displayed reduction of brain lesions. Although chloroquine treatment reduced parasitaemia, there was increased production of proinflammatory cytokines and damage in the CNS not observed with A. blazei treatment. Moreover, the in vitro pretreatment of infected erythrocytes followed by in vivo infection resulted in lower parasitaemia, increased survival, and little evidence of clinical signs of disease. Conclusions: This study strongly suggests that the administration of A. blazei (aqueous extract or fraction C) was effective in improving the consequences of CM in mice and may provide novel therapeutic strategies.

Original languageEnglish (US)
Article number311
JournalMalaria Journal
Volume14
Issue number1
DOIs
StatePublished - Aug 11 2015

Fingerprint

Agaricus
Cerebral Malaria
Agaricales
Parasitemia
Plasmodium berghei
Chloroquine
Cytokines
Therapeutics
Complementary Therapies
Interleukin-1
Inbred C57BL Mouse
Drug Resistance
Weight Loss
Interleukin-6
Anti-Inflammatory Agents
Antioxidants
Erythrocytes
Body Weight
Brain
Infection

Keywords

  • Agaricus blazei Murrill
  • Anti-malarial therapy
  • Experimental cerebral malaria
  • Immunomodulation

ASJC Scopus subject areas

  • Infectious Diseases
  • Parasitology

Cite this

Val, C. H., Brant, F., Miranda, A. S., Rodrigues, F. G., Oliveira, B. C. L., Santos, E. A., ... Machado, F. S. (2015). Effect of mushroom Agaricus blazei on immune response and development of experimental cerebral malaria. Malaria Journal, 14(1), [311]. https://doi.org/10.1186/s12936-015-0832-y

Effect of mushroom Agaricus blazei on immune response and development of experimental cerebral malaria. / Val, Cynthia H.; Brant, Fátima; Miranda, Aline S.; Rodrigues, Flávia G.; Oliveira, Bruno C L; Santos, Elândia A.; Assis, Diego R R; Esper, Lísia; Silva, Bruno C.; Rachid, Milene A.; Tanowitz, Herbert B.; Teixeira, Antônio L.; Teixeira, Mauro M.; Régis, Wiliam C B; Machado, Fabiana S.

In: Malaria Journal, Vol. 14, No. 1, 311, 11.08.2015.

Research output: Contribution to journalArticle

Val, CH, Brant, F, Miranda, AS, Rodrigues, FG, Oliveira, BCL, Santos, EA, Assis, DRR, Esper, L, Silva, BC, Rachid, MA, Tanowitz, HB, Teixeira, AL, Teixeira, MM, Régis, WCB & Machado, FS 2015, 'Effect of mushroom Agaricus blazei on immune response and development of experimental cerebral malaria', Malaria Journal, vol. 14, no. 1, 311. https://doi.org/10.1186/s12936-015-0832-y
Val, Cynthia H. ; Brant, Fátima ; Miranda, Aline S. ; Rodrigues, Flávia G. ; Oliveira, Bruno C L ; Santos, Elândia A. ; Assis, Diego R R ; Esper, Lísia ; Silva, Bruno C. ; Rachid, Milene A. ; Tanowitz, Herbert B. ; Teixeira, Antônio L. ; Teixeira, Mauro M. ; Régis, Wiliam C B ; Machado, Fabiana S. / Effect of mushroom Agaricus blazei on immune response and development of experimental cerebral malaria. In: Malaria Journal. 2015 ; Vol. 14, No. 1.
@article{6a0c1a63a0ed495ea9f83d6f0e40685c,
title = "Effect of mushroom Agaricus blazei on immune response and development of experimental cerebral malaria",
abstract = "Background: Cerebral malaria (CM) is debilitating and sometimes fatal. Disease severity has been associated with poor treatment access, therapeutic complexity and drug resistance and, thus, alternative therapies are increasingly necessary. In this study, the effect of the administration of Agaricus blazei, a mushroom of Brazilian origin in a model of CM caused by Plasmodium berghei, strain ANKA, was investigated in mice. Methods: C57BL/6 mice were pre-treated with aqueous extract or fractions of A. blazei, or chloroquine, infected with P. berghei ANKA and then followed by daily administration of A. blazei or chloroquine. Parasitaemia, body weight, survival and clinical signs of the disease were evaluated periodically. The concentration of pro-and anti-inflammatory cytokines, histopathology and in vitro analyses were performed. Results: Mice treated with A. blazei aqueous extract or fraction C, that shows antioxidant activity, displayed lower parasitaemia, increased survival, reduced weight loss and protection against the development of CM. The administration of A. blazei resulted in reduced levels of TNF, IL-1β and IL-6 production when compared to untreated P. berghei-infected mice. Agaricus blazei (aqueous extract or fraction C) treated infected mice displayed reduction of brain lesions. Although chloroquine treatment reduced parasitaemia, there was increased production of proinflammatory cytokines and damage in the CNS not observed with A. blazei treatment. Moreover, the in vitro pretreatment of infected erythrocytes followed by in vivo infection resulted in lower parasitaemia, increased survival, and little evidence of clinical signs of disease. Conclusions: This study strongly suggests that the administration of A. blazei (aqueous extract or fraction C) was effective in improving the consequences of CM in mice and may provide novel therapeutic strategies.",
keywords = "Agaricus blazei Murrill, Anti-malarial therapy, Experimental cerebral malaria, Immunomodulation",
author = "Val, {Cynthia H.} and F{\'a}tima Brant and Miranda, {Aline S.} and Rodrigues, {Fl{\'a}via G.} and Oliveira, {Bruno C L} and Santos, {El{\^a}ndia A.} and Assis, {Diego R R} and L{\'i}sia Esper and Silva, {Bruno C.} and Rachid, {Milene A.} and Tanowitz, {Herbert B.} and Teixeira, {Ant{\^o}nio L.} and Teixeira, {Mauro M.} and R{\'e}gis, {Wiliam C B} and Machado, {Fabiana S.}",
year = "2015",
month = "8",
day = "11",
doi = "10.1186/s12936-015-0832-y",
language = "English (US)",
volume = "14",
journal = "Malaria Journal",
issn = "1475-2875",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Effect of mushroom Agaricus blazei on immune response and development of experimental cerebral malaria

AU - Val, Cynthia H.

AU - Brant, Fátima

AU - Miranda, Aline S.

AU - Rodrigues, Flávia G.

AU - Oliveira, Bruno C L

AU - Santos, Elândia A.

AU - Assis, Diego R R

AU - Esper, Lísia

AU - Silva, Bruno C.

AU - Rachid, Milene A.

AU - Tanowitz, Herbert B.

AU - Teixeira, Antônio L.

AU - Teixeira, Mauro M.

AU - Régis, Wiliam C B

AU - Machado, Fabiana S.

PY - 2015/8/11

Y1 - 2015/8/11

N2 - Background: Cerebral malaria (CM) is debilitating and sometimes fatal. Disease severity has been associated with poor treatment access, therapeutic complexity and drug resistance and, thus, alternative therapies are increasingly necessary. In this study, the effect of the administration of Agaricus blazei, a mushroom of Brazilian origin in a model of CM caused by Plasmodium berghei, strain ANKA, was investigated in mice. Methods: C57BL/6 mice were pre-treated with aqueous extract or fractions of A. blazei, or chloroquine, infected with P. berghei ANKA and then followed by daily administration of A. blazei or chloroquine. Parasitaemia, body weight, survival and clinical signs of the disease were evaluated periodically. The concentration of pro-and anti-inflammatory cytokines, histopathology and in vitro analyses were performed. Results: Mice treated with A. blazei aqueous extract or fraction C, that shows antioxidant activity, displayed lower parasitaemia, increased survival, reduced weight loss and protection against the development of CM. The administration of A. blazei resulted in reduced levels of TNF, IL-1β and IL-6 production when compared to untreated P. berghei-infected mice. Agaricus blazei (aqueous extract or fraction C) treated infected mice displayed reduction of brain lesions. Although chloroquine treatment reduced parasitaemia, there was increased production of proinflammatory cytokines and damage in the CNS not observed with A. blazei treatment. Moreover, the in vitro pretreatment of infected erythrocytes followed by in vivo infection resulted in lower parasitaemia, increased survival, and little evidence of clinical signs of disease. Conclusions: This study strongly suggests that the administration of A. blazei (aqueous extract or fraction C) was effective in improving the consequences of CM in mice and may provide novel therapeutic strategies.

AB - Background: Cerebral malaria (CM) is debilitating and sometimes fatal. Disease severity has been associated with poor treatment access, therapeutic complexity and drug resistance and, thus, alternative therapies are increasingly necessary. In this study, the effect of the administration of Agaricus blazei, a mushroom of Brazilian origin in a model of CM caused by Plasmodium berghei, strain ANKA, was investigated in mice. Methods: C57BL/6 mice were pre-treated with aqueous extract or fractions of A. blazei, or chloroquine, infected with P. berghei ANKA and then followed by daily administration of A. blazei or chloroquine. Parasitaemia, body weight, survival and clinical signs of the disease were evaluated periodically. The concentration of pro-and anti-inflammatory cytokines, histopathology and in vitro analyses were performed. Results: Mice treated with A. blazei aqueous extract or fraction C, that shows antioxidant activity, displayed lower parasitaemia, increased survival, reduced weight loss and protection against the development of CM. The administration of A. blazei resulted in reduced levels of TNF, IL-1β and IL-6 production when compared to untreated P. berghei-infected mice. Agaricus blazei (aqueous extract or fraction C) treated infected mice displayed reduction of brain lesions. Although chloroquine treatment reduced parasitaemia, there was increased production of proinflammatory cytokines and damage in the CNS not observed with A. blazei treatment. Moreover, the in vitro pretreatment of infected erythrocytes followed by in vivo infection resulted in lower parasitaemia, increased survival, and little evidence of clinical signs of disease. Conclusions: This study strongly suggests that the administration of A. blazei (aqueous extract or fraction C) was effective in improving the consequences of CM in mice and may provide novel therapeutic strategies.

KW - Agaricus blazei Murrill

KW - Anti-malarial therapy

KW - Experimental cerebral malaria

KW - Immunomodulation

UR - http://www.scopus.com/inward/record.url?scp=84938834123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938834123&partnerID=8YFLogxK

U2 - 10.1186/s12936-015-0832-y

DO - 10.1186/s12936-015-0832-y

M3 - Article

C2 - 26260055

AN - SCOPUS:84938834123

VL - 14

JO - Malaria Journal

JF - Malaria Journal

SN - 1475-2875

IS - 1

M1 - 311

ER -